 |
|
|
| |
C-BREEZE 1: Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection
|
| |
| |
Reported by Jules Levin
Presented at The Liver Meeting® 2017; Washington, DC; October 20-24, 2017
Eric Lawitz1; Fred Poordad1; Leah J. Anderson2; Michelle Vesay2; Hong Liu2; Ernest Asante-Appiah2; Wei Gao2; Doreen Fernsler2; Michael Robertson2; George J. Hanna2; Eliav Barr2; Joan R. Butterton2; Kris Kowdley3;
Tarek Hassanein4; Amandeep Sahota5; Stuart Gordon6; Wendy W. Yeh2
1Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX, USA; 2Merck & Co., Inc., Kenilworth, NJ, USA; 3Swedish Medical Center, Seattle, WA, USA; 4Southern California GI and Liver Center, Coronado, CA, USA; 5Southern California Kaiser Permanente, Los Angeles, CA, USA; 6Henry Ford Hospital, Detroit, MI, USA
|
| |
|
|
|
|
|
